Nicki Thompson
Chief Executive Officer Trimtech Therapeutics
Seminars
Thursday 30th October 2025
Panel Discussion: Beyond CRBN & VHL: Harnessing Novel Ligases for Next-Gen Drug Discovery
11:00 am
- What criteria and validation strategies should be used to determine whether a novel E3 ligase is suitable for therapeutic development?
- In what ways do novel ligases offer functional or pharmacological advantages over traditional ligases like CRBN or VHL?
- How can we build a compelling case—biologically and commercially—for prioritizing a novel ligase over established workhorses in drug development pipelines?
Thursday 30th October 2025
Harnessing the Innate Properties of Novel E3 Ligase Trim21 for the Development of Treatments for Neurodegenerative Diseases
1:00 pm
- Why TRIM 21 is ideally suited to selectively degrading protein aggregates which underpin so many neurodegenerative diseases
- TrimTech’s approach to validating targets and TRIM21’s role in degrading these targets with a range of modalities
- TrimTech’s strategies and progress developing therapeutic degraders known as a TRIMTACTM or TRIMGLUETM for neurodegenerative and inflammatory diseases
